HemOnc.org - A Free Hematology/Oncology Reference

HemOnc.org is the largest freely available medical wiki of interventions, regimens, and general information relevant to the fields of hematology and oncology. Any healthcare professional can sign up to contribute; the accuracy and completeness of content is overseen by the Editorial Board. If this is your first time visiting, please start with the the tutorial page, review our philosophy, or just start exploring!
Regimens: 5,315 Guidelines: 1,217 Studies: 6,820 References: 7,828
Solid Tumors Malignant Hematology Pediatrics Transplant & IEC Classical Hematology

Links to all main disease pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, ER-positive Breast cancer, HER2-positive Breast cancer, ER and HER2 co-expressing
Breast cancer, triple negative (TNBC) Breast cancer, BRCA-mutated Breast cancer, PIK3CA-mutated
Dermatologic Oncology
Cutaneous BCC Cutaneous SCC Melanoma Melanoma, BRAF-mutated
Melanoma, KIT-mutated Melanoma, NRAS-mutated Merkel cell carcinoma (MCC) Uveal melanoma
Endocrine Oncology
Adrenocortical carcinoma Neuroendocrine tumor (NET) Neuroendocrine carcinoma (NEC) Pancreatic NET
Pheochromocytoma Thyroid cancer Differentiated thyroid cancer (DTC) Medullary thyroid cancer (MTC)
Thyroid cancer, BRAF-mutated Thyroid cancer, RET-positive
Gastrointestinal Oncology, Intestinal
Anal cancer Appendiceal tumor Colon cancer Colon cancer, RAS wild-type
Colorectal cancer (CRC) CRC, BRAF-mutated CRC, HER2-positive CRC, MSI-H or dMMR
CRC, RAS wild-type Esophageal cancer Esophageal adenocarcinoma Esophageal SCC
Gastric cancer Gastric cancer, HER2-positive Rectal cancer Small bowel adenocarcinoma
Gastrointestinal Oncology, Extraintestinal
Cholangiocarcinoma Gallbladder cancer Hepatocellular carcinoma (HCC) Periampullary adenocarcinoma
Pancreatic adenocarcinoma Pancreatic adenocarcinoma, BRCA-mutated Pancreatic NET
Genitourinary Oncology
Penile cancer Prostate cancer Prostate cancer, BRCA-mutated Testicular cancer
Renal cell carcinoma (RCC) Clear cell RCC (ccRCC) Non-clear cell RCC (nccRCC) Papillary RCC
Sarcomatoid RCC VHL-associated RCC
Urothelial carcinoma Bladder cancer Upper tract urothelial carcinoma (UTUC)
Gynecologic Oncology
Cervical cancer Endometrial cancer Gestational trophoblastic neoplasia Low-grade serous ovarian cancer (LGSOC)
Ovarian cancer Ovarian cancer, BRCA-mutated Vulvar cancer
Head & Neck Oncology
Head and neck cancer Nasopharyngeal carcinoma (NPC) HPV+ Oropharyngeal cancer
Mesothelioma
Malignant peritoneal mesothelioma (MPEM) Malignant pleural mesothelioma (MPM)
Neuro-Oncology
Anaplastic glioma Craniopharyngioma Glioblastoma (GBM) Low-grade glioma
Meningioma Subependymal giant cell astrocytoma (SEGA)
CNS carcinoma CNS leukemia CNS lymphoma CNS melanoma
Sarcoma
Bone sarcoma Ewing sarcoma Giant-cell tumor of bone Osteosarcoma
Soft tissue sarcoma (STS) Alveolar soft part sarcoma (ASPS) Dermatofibrosarcoma protuberans Desmoid tumor
Epithelioid sarcoma Gastrointestinal stromal tumor (GIST) Inflammatory myofibroblastic tumor (IMT) Leiomyosarcoma (LMS)
Liposarcoma PEComa Rhabdomyosarcoma (RMS) Tenosynovial giant cell tumor (TGCT)
Vascular sarcoma Angiosarcoma Kaposi sarcoma (KS)
Thoracic Oncology
Non-small cell lung cancer (NSCLC) NSCLC, nonsquamous NSCLC, squamous NSCLC, ALK-positive
NSCLC, BRAF-mutated NSCLC, EGFR-mutated NSCLC, HER2-mutated NSCLC, KRAS-mutated
NSCLC, MET-mutated NSCLC, RET-positive NSCLC, ROS1-positive NSCLC, CNS metastases
Small cell lung cancer (SCLC) Thymoma
Site-agnostic
BRAF EGFR ERBB2 (HER2) ERBB3 (HER3)
MSI-H or dMMR NTRK RET SMO or PTCH-1 (Hedgehog)
TMB-H Carcinoma of unknown primary (CUP)

Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) AML, FLT3-positive AML, IDH-mutated AML, NPM1-mutated
Acute promyelocytic leukemia (APL) B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myeloid leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome (MDS) Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma Classical Hodgkin lymphoma (cHL) CNS lymphoma Diffuse large B-cell lymphoma (DLBCL)
High-grade B-cell lymphoma HIV-associated lymphoma Mantle cell lymphoma (MCL) Mediastinal gray-zone lymphoma (MGZL)
Primary mediastinal B-cell lymphoma (PMBL) Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
MALT lymphoma Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (main page) MM, induction MM, consolidation & maintenance
MM, relapsed/refractory Plasma cell leukemia (PCL) POEMS syndrome Smoldering multiple myeloma (SMM)
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT
Large granular lymphocytic (LGL) leukemia NK- and T-cell lymphoma (NKTCL) Peripheral T-cell Lymphoma (PTCL) T-cell acute lymphoblastic lymphoma (T-LBL)
T-cell prolymphocytic lymphoma (T-PLL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocytic disorders
Erdheim-Chester disease (ECD) Hemophagocytic lymphohistiocytosis (HLH) Langerhans cell histiocytosis (LCH) Rosai-Dorfman-Destombes disease

Pediatric Neoplasms
Pediatric CNS malignancies
Low-grade glioma High-grade glioma Medulloblastoma
Pediatric hematologic neoplasms
B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL) Acute myeloid leukemia (AML)
Anaplastic large cell lymphoma (ALCL) Chronic myeloid leukemia (CML) Juvenile myelomonocytic leukemia (JMML)
Classical Hodgkin lymphoma (cHL) Non-Hodgkin lymphoma (NHL)
Pediatric solid tumors
Epithelioid sarcoma Ewing sarcoma Hepatoblastoma Neuroblastoma
Osteosarcoma Rhabdomyosarcoma Wilms tumor

Transplant and Immune Effector Cells (IECs)
Stem cell mobilization Allogeneic HSCT Autologous HSCT Chimeric antigen receptor T cells (CAR-T)
Graft versus host disease (GVHD) Hepatic veno-occlusive disease (VOD/SOS)

Classical Hematology
Hemostasis and thrombosis
Acquired coagulopathy Acquired thrombotic thrombocytopenic purpura (aTTP) Antiphospholipid antibody syndrome (APLAS) Congenital thrombotic thrombocytopenic purpura (cTTP)
Heparin-induced thrombocytopenia (HIT) Hereditary hemorrhagic telangiectasia (HHT) Inherited coagulopathy Inherited thrombophilia
Thrombotic microangiopathy (TMA) Venous thromboembolism (VTE)
Cytopenias
Aplastic anemia Autoimmune cytopenia Immune thrombocytopenia (ITP) Thrombocytopenia in liver disease
WHIM syndrome
Hemolytic disorders and Hemoglobinopathies
Atypical hemolytic uremic syndrome (aHUS) Warm autoimmune hemolytic anemia (WAIHA) Cold agglutinin disease (CAD) Paroxysmal nocturnal hemoglobinuria (PNH)
Pyruvate kinase deficiency (PKD) Beta thalassemia Sickle cell anemia

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.

Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.

Priorities of this project include:


Additional possibilities for this project may include:

  • Creating synopses of pivotal clinical trials and regimens
  • Prioritizing regimens by their efficacy and/or toxicity
  • Capturing historical regimens that were standard-of-care prior to 2005
  • Checklists for common clinical scenarios/diseases
  • Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.